A patient who has not had a visit in six months is requesting a refill of levetiracetam 750 mg; should I require an in‑person or telehealth appointment before providing the refill?

Yes, require a visit before refilling levetiracetam after a 6-month gap

You should schedule an appointment (in-person or telehealth) before providing the refill for this patient who has not been seen in 6 months. This aligns with standard practice for antiepileptic drug (AED) management and addresses both safety monitoring requirements and regulatory considerations for controlled medication prescribing.

Rationale for Requiring a Visit

Safety Monitoring Requirements

Levetiracetam requires systematic monitoring despite its favorable safety profile. The FDA label clearly documents that patients need assessment for:

• Neuropsychiatric adverse events including behavioral changes (aggression, agitation, depression, psychotic symptoms) which occur in 13.3% of adult patients 1
• Hematologic abnormalities with statistically significant decreases in WBC, neutrophil counts, and RBC parameters 1
• Suicidal ideation risk as with all AEDs, requiring monitoring for emergence or worsening of depression and suicidal thoughts 1

These side effects necessitate regular clinical evaluation, not just prescription renewal.

Establishing Valid Patient-Physician Relationship

The American College of Physicians guidelines emphasize that a valid patient-physician relationship must be maintained for professionally responsible care 2. While telehealth can establish or maintain this relationship through real-time audiovisual technology, a 6-month gap without contact raises questions about continuity of care. The guideline specifically states physicians must "take appropriate steps to establish a relationship based on the standard of care required for an in-person visit" 2.

Seizure Control Assessment

For patients on AEDs, regular follow-up is essential to:

• Evaluate seizure frequency and control
• Assess medication adherence (a common issue with AEDs)
• Monitor for breakthrough seizures that might require dose adjustment
• Document any changes in seizure patterns

The NCCN guidelines for CNS conditions note that patients should be closely monitored for any adverse effects of AEDs and that many AEDs have significant drug interactions requiring ongoing assessment 3.

Visit Format: Telehealth vs In-Person

Telehealth is appropriate for this medication management visit given the clinical context 4, 5. Recent evidence demonstrates that:

• Telehealth is specifically useful for medication management and follow-up visits for non-complicated epilepsy care 4
• Medication prescribing occurs in 38.4% of video visits and 34.6% of telephone visits, demonstrating feasibility 6
• Comprehensive medication management can be effectively delivered via telehealth when properly structured 5

When In-Person Would Be Preferred

Consider requiring an in-person visit if the patient:

• Has had recent seizures or breakthrough events
• Reports new neuropsychiatric symptoms
• Has comorbid medical complexity
• Requires physical examination for new symptoms
• Has a neurostimulation device needing assessment 4

Practical Approach

During the Visit (Telehealth or In-Person)

1. Seizure history: Document seizure frequency over the past 6 months, any breakthrough events, triggers, or pattern changes

2. Medication adherence: Assess compliance with the 750mg dosing regimen and identify any barriers

3. Systematic side effect assessment 1:

   • Behavioral changes: aggression, agitation, depression, irritability, anxiety
   • Somnolence and fatigue (reported in 14.8% of patients)
   • Coordination difficulties
   • Suicidal ideation screening

4. Drug interactions: Review all current medications, as levetiracetam has minimal interactions but other AEDs may affect its metabolism 1

5. Laboratory monitoring: Consider ordering CBC if not done recently, given the hematologic effects 1

6. Establish follow-up schedule: The stimulant medication guidelines (applicable principle) recommend monthly appointments until symptoms are stabilized 7. For stable epilepsy patients, visits every 3-6 months are standard.

Common Pitfalls to Avoid

• Don't simply refill without contact: This creates gaps in monitoring for serious adverse events and fails to maintain the therapeutic relationship
• Don't assume stability: Six months without contact means you lack current information about seizure control and side effects
• Don't overlook psychiatric screening: Neuropsychiatric events are common with levetiracetam and require active inquiry 1
• Don't forget documentation: Document your assessment of seizure control, side effects, and rationale for continuing current dose

Regulatory Considerations

While the COVID-19 pandemic guidelines 8 emphasized ensuring patients receive appropriate prescriptions to avoid withdrawal, this applies more to situations of acute access disruption rather than routine refills after prolonged gaps in care. The principle of ensuring continuity while maintaining safety standards means scheduling a visit rather than automatic refill.

The American College of Physicians position emphasizes that convenience should not compromise the standard of care 2. A 6-month gap exceeds reasonable intervals for AED monitoring, making a visit medically necessary rather than optional.